Sonablate

Sonablate®

Urology A device that uses high-intensity focused ultrasound–HIFU technology, combining focused ultrasound beams and imaging, to heat and destroy targeted tissue without affecting surrounding healthy tissue Indications Treatment of BPH. See Benign prostatic hypertrophy.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration (FDA) regulatory authorization for prostate tissue ablation with the Sonablate HIFU device.
HIFU treatment was performed using the Sonablate 500 machine (SonaCare Medical, Charlotte, NC).
The Center of Excellence will provide physician training and proctoring along with clinical studies, patient satisfaction research and advanced technology development associated with two innovative HIFU systems: the Sonatherm laparoscopic HIFU surgical ablation system and the Sonablate 500 transrectal HIFU surgical ablation system.
The developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions said it has introduced its Sonablate 500 for prostate cancer into the European market.
Misonix develops, manufactures, and markets medical, scientific and industrial ultrasonic and air pollution systems and maintains a minority equity position in Focus Surgery as its exclusive manufacturer of the Sonablate 500.
Focus Surgery entered into an exclusive International Distribution Agreement, outside of Asia and the United States, with Endocare Corporation for its Sonablate 500 unit, which treats prostate cancer and Benign Prostatic Hyperplasia (BPH) using High Intensity Focused Ultrasound, (HIFU).
The partnership will give physicians and their patients access to Sonablate HIFU technology for non-invasive prostate cancer treatment at a surgery center in Huntersville, NC.
Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer.
Scionti has collaborated with leading medical treatment centers around the world to help perfect HIFU technology and served as director of Clinical Education and Training for USHIFU and SonaCare Medical, the manufacturer of the Sonablate, the first HIFU device to receive U.
22] and "HIFU using the Sonablate 500 carries little risk of side effects like impotence and incontinence.
its plans for growing the Sonablate HIFU technology in Europe include rolling out state-of-the-art Sonablate 500 machines; infusing both capital and human resources to significantly increase access to Sonablate HIFU; expanding the base of European Sonablate users; and increasing the existing clinical data registry.
The patient was treated with salvage high-intensity focused ultrasound (HIFU) as part of a phase II trial, using the Sonablate 500 Console (Focus Surgery, Inc.